Patents Assigned to FORENDO PHARMA LTD
  • Publication number: 20220127303
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 11, 2022
    Publication date: April 28, 2022
    Applicant: FORENDO PHARMA LTD
    Inventors: Leena HIRVELÄ, Marjo HAKOLA, Tero LINNANEN, Pasi KOSKIMIES, Camilla STJERNSCHANTZ
  • Patent number: 11254703
    Abstract: The invention relates to compounds of formula (II), and pharmaceutically acceptable salts thereof, wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 22, 2022
    Assignee: FORENDO PHARMA LTD
    Inventors: Leena Hirvelä, Marjo Hakola, Tero Linnanen, Pasi Koskimies, Camilla Stjernschantz
  • Publication number: 20200317718
    Abstract: The invention relates to compounds of formula (II), and pharmaceutically acceptable salts thereof, wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 5, 2020
    Publication date: October 8, 2020
    Applicant: FORENDO PHARMA LTD
    Inventors: Leena HIRVELÄ, Marjo HAKOLA, Tero LINNANEN, Pasi KOSKIMIES, Camilla STJERNSCHANTZ
  • Patent number: 10717761
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: July 21, 2020
    Assignee: FORENDO PHARMA LTD
    Inventors: Leena Hirvelä, Marjo Hakola, Tero Linnanen, Pasi Koskimies, Camilla Stjernschantz
  • Patent number: 10626140
    Abstract: The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: April 21, 2020
    Assignee: Forendo Pharma LTD
    Inventors: Leena Hirvelä, Pasi Koskimies, Risto Lammintausta, Marjo Hakola, Maire Eloranta
  • Patent number: 10413557
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 17, 2019
    Assignee: FORENDO PHARMA LTD.
    Inventors: Leena Hirvelä, Pasi Koskimies, Risto Lammintausta, Marjo Hakola, Maire Eloranta
  • Patent number: 10377791
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: August 13, 2019
    Assignee: FORENDO PHARMA LTD.
    Inventors: Maire Eloranta, Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
  • Publication number: 20180354984
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 7, 2018
    Publication date: December 13, 2018
    Applicant: FORENDO PHARMA LTD
    Inventors: Leena HIRVELÄ, Marjo HAKOLA, Tero LINNANEN, Pasi KOSKIMIES, Camilla STJERNSCHANTZ
  • Publication number: 20180265541
    Abstract: The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration.
    Type: Application
    Filed: December 22, 2015
    Publication date: September 20, 2018
    Applicant: FORENDO PHARMA LTD
    Inventors: Leena HIRVELÄ, Pasi KOSKIMIES, Risto Lammintausta, Marjo HAKOLA, Maire ELORANTA
  • Patent number: 9850272
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 26, 2017
    Assignee: FORENDO PHARMA LTD.
    Inventors: Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
  • Publication number: 20170354664
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 14, 2017
    Applicant: FORENDO PHARMA LTD
    Inventors: Leena HIRVELÄ, Pasi KOSKIMIES, Risto Lammintausta, Marjo HAKOLA, Maire ELORANTA
  • Patent number: 9663549
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: May 30, 2017
    Assignee: FORENDO PHARMA LTD.
    Inventors: Maire Eloranta, Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
  • Publication number: 20170114090
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 25, 2014
    Publication date: April 27, 2017
    Applicant: FORENDO PHARMA LTD
    Inventors: Maire ELORANTA, Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto Lammintausta, Mikko Unkila
  • Publication number: 20170081357
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 25, 2014
    Publication date: March 23, 2017
    Applicant: FORENDO PHARMA LTD
    Inventors: Maire ELORANTA, Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto LAMMINTAUSTA, Mikko UNKILA
  • Publication number: 20170081356
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 25, 2014
    Publication date: March 23, 2017
    Applicant: FORENDO PHARMA LTD
    Inventors: Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto LAMMINTAUSTA, Mikko UNKILA